Miranda Orr, Valentina Garbarino, Juan Palavicini, Justin Melendez, Nicolas Barthélemy, Yingxin He, Tiffany Kautz, Marisa Lopez-Cruzan, Julia Mathews, Peng Xu, Bin Zhang, Afaf Saliba, Nagarjunachary Ragi, Kumar Sharma, Suzanne Craft, Ronald C Petersen, Jair Espindola-Netto, Ailing Xue, Tamara Tchkonia, James Kirkland, Sudha Seshadri, Arash Salardini, Nicolas Musi, Randall Bateman, Mitzi Gonzales
Senescent cell accumulation contributes to the progression of age-related disorders including Alzheimer's disease (AD). Clinical trials evaluating senolytics, drugs that clear senescent cells, are underway, but lack standardized outcome measures. Our team recently published data from the first open-label trial to evaluate senolytics (dasatinib plus quercetin) in AD. After 12-weeks of intermittent treatment, we reported brain exposure to dasatinib, favorable safety and tolerability, and modest post-treatment changes in cerebrospinal fluid (CSF) inflammatory and AD biomarkers using commercially available assays...
March 8, 2024: Research Square